On May 5, 2021, Hoth Therapeutics announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

The expanded research agreement focused on investigating the potential of HT-002 to inhibit SARS-CoV-2 virus variants. This work was informed by the molecular modeling of SARS-CoV-2 spike peptide sequences from strain variants, reported in an earlier preprint publication in bioRxiv.

Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth’s pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.